title: Prophylactic treatment effects on inhibitor risk: experience in one centre.
abstract: Nowadays, the elective treatment for children with haemophilia is prophylaxis. There is a common consensus that this modality of therapeutic approach is not associated with a higher risk of inhibitor development. We analysed the inhibitor incidence in 50 haemophiliac children and its relationship with mutations, type of clotting factor used and treatment modality. There was a significant correlation between receiving on-demand treatment and an increased incidence of inhibitors, independently of mutations or factor used. We advise putting haemophiliac children under prophylactic treatment as soon as possible, especially if they have mutations associated with high risk of inhibitor development, as prophylaxis is negatively associated with the development of inhibitors.
authors.affiliation: Congenital Coagulopathy Section, Haematology Service, Universitary Hospital 'La Paz', Madrid, Spain. martamorado@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Morado
authors.forename: A
authors.initials: A
authors.lastname: Villar
authors.forename: V
authors.initials: V
authors.lastname: Jiménez Yuste
authors.forename: M
authors.initials: M
authors.lastname: Quintana
authors.forename: F
authors.initials: F
authors.lastname: Hernandez Navarro
mesh_terms: D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D006395:Hemarthrosis / Q000209:etiology / Q000517:prevention & control*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D007275:Injections, Intravenous; D009154:Mutation; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D001779:Blood Coagulation Factors; C078147:F8 protein, human; D005169:Factor VIII